Wave Life Sciences, a small pharmaceutical company, saw its stock surge following the Federal Reserve’s rate cut. The company’s focus on developing a treatment for Duchenne Muscular Dystrophy (DMD) with its drug WVE-N531, combined with analyst predictions of an 85% upside potential, has fueled investor excitement. This article dives into the progress of Wave’s DMD treatment, its financial standing, and key factors to watch in the future.